Cantor Fitzgerald Has Positive View of Amgen FY2025 Earnings

Amgen Inc. (NASDAQ:AMGN) – Stock analysts at Cantor Fitzgerald upped their FY2025 EPS estimates for Amgen in a research report issued to clients and investors on Friday, May 2nd. Cantor Fitzgerald analyst C. Gould now anticipates that the medical research company will earn $20.85 per share for the year, up from their previous forecast of $20.50. Cantor Fitzgerald has a “Neutral” rating and a $305.00 price target on the stock. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share.

AMGN has been the topic of several other reports. Citigroup reiterated a “neutral” rating on shares of Amgen in a research report on Wednesday, February 5th. Morgan Stanley reaffirmed an “equal weight” rating on shares of Amgen in a research note on Friday. Piper Sandler upped their price objective on shares of Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Royal Bank of Canada reduced their price target on Amgen from $324.00 to $320.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. Finally, Bank of America increased their target price on Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a research report on Wednesday, March 5th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Amgen currently has a consensus rating of “Hold” and an average price target of $308.18.

Amgen Trading Down 3.4 %

NASDAQ:AMGN opened at $270.56 on Monday. The company has a market capitalization of $145.47 billion, a PE ratio of 35.84, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. Amgen has a 52-week low of $253.30 and a 52-week high of $346.85. The stock has a fifty day simple moving average of $298.42 and a 200-day simple moving average of $290.64. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Amgen’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the company earned $3.96 earnings per share.

Institutional Investors Weigh In On Amgen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Talbot Financial LLC boosted its stake in shares of Amgen by 5.6% during the 4th quarter. Talbot Financial LLC now owns 42,791 shares of the medical research company’s stock worth $11,153,000 after acquiring an additional 2,274 shares in the last quarter. Ascent Wealth Partners LLC lifted its stake in Amgen by 0.7% during the fourth quarter. Ascent Wealth Partners LLC now owns 9,024 shares of the medical research company’s stock valued at $2,352,000 after buying an additional 64 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Amgen by 6.0% in the third quarter. Principal Financial Group Inc. now owns 635,172 shares of the medical research company’s stock worth $204,659,000 after acquiring an additional 35,785 shares in the last quarter. ICICI Prudential Asset Management Co Ltd boosted its stake in Amgen by 242.2% in the 4th quarter. ICICI Prudential Asset Management Co Ltd now owns 23,999 shares of the medical research company’s stock worth $6,255,000 after purchasing an additional 16,985 shares during the period. Finally, PFW Advisors LLC acquired a new stake in shares of Amgen in the fourth quarter worth $1,105,000. Institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other news, EVP David M. Reese sold 25,225 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the transaction, the executive vice president now directly owns 36,922 shares in the company, valued at approximately $11,240,533.68. The trade was a 40.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of Amgen stock in a transaction on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the sale, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. The trade was a 46.35 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 67,752 shares of company stock worth $20,160,532. Insiders own 0.69% of the company’s stock.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.52%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s payout ratio is 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.